^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

evixapodlin (GS-4224)

i
Other names: GS-4224, OX-4224, OX4224, OX 4224
Associations
Trials
Company:
Gilead, OmRx Oncology
Drug class:
PD-L1 inhibitor
Related drugs:
Associations
Trials
over3years
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1b/2, N=18, Terminated, Gilead Sciences | N=120 --> 18 | Trial completion date: May 2023 --> Mar 2021 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Mar 2021; Gilead decision to terminate
Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • MSI-H/dMMR
|
evixapodlin (GS-4224)
almost4years
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1b/2, N=120, Recruiting, Gilead Sciences | Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Jul 2022 --> Apr 2023
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • MSI-H/dMMR
|
evixapodlin (GS-4224)
over4years
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1b/2, N=82, Recruiting, Gilead Sciences | Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Nov 2021 --> Jul 2022
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • MSI-H/dMMR
|
evixapodlin (GS-4224)
over4years
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1b/2, N=76, Recruiting, Gilead Sciences | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Nov 2021
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • MSI-H/dMMR
|
evixapodlin (GS-4224)